Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where  Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year.  The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products.  Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year.  Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXXXXXXXXX XXXXXXX:
XXXXX XXXXXXX XXXXXX XXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXXXXXXX XXXXXXXXX XX £ X.X XXXXXXX, XX X%. XXXXX XXXXX XX XXXXXXXX/XXXXXX, XXX XXXXXX XXX XXXX, XXXX XX% XX £X.X XXXXXXX. XXXXX XX XXX XXX XXXX X% XX £X.X XXXXXXX, XX XXXXXX, XXXX X% XX £X.X XXXXXXX XXX XX XXXXXXXXXXXXX XXXXXXX, XXXX XX% XX £XXX XXXXXXX, XXXXXXXX XX XXX XXXXXX XX XXXXX XX XXXX.

XXXXXXXX/XXXXXX XXXXXX XXXXX XX XXXXX XX XXX XXXX-XXXXXX XXX XXXX XXXXXXX XXXXX XXX XX% XX XXXXXX XXX XX% XX XXX XXX.

XXXXXX: XX XXXX XXXXXXX (X XXX XXXX):
XXXXXXXX/XXXXXX XXXXX XX XX% XX £X.X XXXXXXX.
XXXXX XX XXXXXXXX/XXXXXX, XXX XXXXXX XXX XXXX, XXXX X% XX £X.X XXXXXXX XX XXX XXX. XX XXXXXX, XXXXX XXXX X% XX £X.X XXXXXXX XXX XX XXXXXXXXXXXXX XXXXX XXXX XX XX% XX £XXX XXXXXXX, XXXXXXXX XX XXX XXXXXX XX XXXXX XX XXXX. XXX XXXXXXXXX XX XXX XXXXXXXXX XXX XX XXXXXXXX/XXXXXX XX XXX XXXXXXXXX XX XXXX XXX XX XX XXXXXXX XXXXXXXXXXX XXXX XXX XXX XX XXXXXX XXX XXXXXXXXXX XXX XXX XX XXXX XXXXXXX XXXXX, XXXXXXXXX XXXXXXXXXX XX XXXX XXXXXXXXXX X XXXXX XXX XXXXXXXXX XX XXXXXXXXXXXXX.

XXXXXX: XX XXXX XXXXXXX XXXXXXX XXXXXXXXXXXX (XX XXX XXXX), XXXXX XX:
XXXXX XXXXXX XXXXX XXXX ‘XX
XXXXXX XXXXXXXXXXX: XXXX
– XX XXXXX XXXXXXXX XXX XXXXX: XXXX ’XX
– XXXXXXXX XXX XX XXX XXX; XXXXX XXXXXX XXXX.

XXXXXXXXXXXXXX® XXXXXXX:
XXXXX XXXXXXX XXXXXX XXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXXXX XX XXXXXXXX/XXXXXX XXX XXXXXX XXX XXXX XXXX X% XX £X.X XXXXXXX. XX XXX XXX, XXXXXX XXXXX XXXX X% XX £X.X XXXXXXX, XXXX X XXXXXX XX XXXXXX XXXXXX XX XXX XXXXXX XXXX XX XXX XXXX. XXXXXX XXXX, XXX XXX XXXXXXX XXXXXX XX XXXXXXXXXX XX XXXX XXX XXXXXXXXXX XX XXXXXXXXXXXXX XXX XXXX XXX XXXXXX XXXX XXX XXXX XXXXXXX XX XXX XXXXXX XXXXXXXX. XX XXXXXX, XXXXX XXXXXXXXX XX X% XX £X.X XXXXXXX. XXXXXX XXXXXXXXXXX XXX XXXXXXXXXXXX XXXXXX XX XXXXXXXX XXXXXXX, XX XX% XX £XXX XXXXXXX, XXX XXXXX, XXXXX XXXXX XX XXX XXXXXXX XXXX XXXX XXXXXXX XX £XX XXXXXXX XXXXXXXXX XXX XXXXXX XX XXXX.

XXXXXX: XX XXXX XXXXXXX ( X XXX XXXX):
XXXXX XX XXXXXXXX/XXXXXX XXX XXXXXX XXX XXXX XXXX X% XX £X.X XXXXXXX. XX XXX XXX, XXXXXX XXXXX XXXX X% XX £X.X XXXXXXX, XXXX X XXXXXX XX XXXXXX XXXXXX XX XXX XXXXXX XXXX XX XXX XXXX. XX XXXXXX, XXXXX XXXXXXXXX XX X% XX £X.X XXXXXXX. XXXXXX XXXXXXXXXXX XXX XXXXXXXXXXXX XXXXXX XX XXXXXXXX XXXXXXX (+XX% XX £XXX XXXXXXX) XXX XXXXX XXXXX XXXXX XX XXX XXXXXXX XXXX XXXX XXXXXXX XX £XX XXXXXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXX  XXXX XXXX XXXXXXX XXXXXXXXXXXX (X XXX XXXX), XXXXX XX:
* XXX XXX XXXXXXXXXX (XXX.‘XX) XXXXX XXXXXXXXXXXX XXX XXXXXX XXXX XX XXXXXXXXXXXX
* XXX XXX XXXXXXXX XXX ‘XX

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXXXX XX XXXXXXX, XXX XXXXXX, XXXX XX% XX £XXX XXXXXXX, XXXX XX XXXXX XX XX% XX £XXX XXXXXXX XXXXXX XX XXXXXXXXX XXX XX XXX XXXXXXX XXX XXXXXXXXXX XX XXXXXXX XXXXXXXXXXXX. XXXXX XX XXXXXX XXXX X% XX
£XXX XXXXXXX XXX XX XXXXXXXXXXXXX XXXX XX% XX £XXX XXXXXXX.

XXXXXX: XX XXXX XXXXXXX (X XXX XXXX):
XXXXX XX XXXXXXX, XXX XXXXXX, XXXX XX% XX £XXX XXXXXXX, XXXX XX XXXXX XX XX% XX £XXX XXXXXXX, XXXXXX XX XXXXXXXXX XXX XX XXX XXXXXXX XXX XXXXXXXXXX XX XXXXXXXXXXXX. XXXXX XX XXXXXX XXXX X% XX £XXX XXXXXXX XXX XX XXXXXXXXXXXXX XXXX XX% XX £XXX XXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXXXX XX XXXXXXX, XXX XXXXXX, XXXX XX% XX £X.X XXXXXXX XXXX XX XXXXX XX XX% XXXXXXXX XXX XXXXXX.

XXXXXX: XX XXXX XXXXXXX (X XXX XXXX):
XXXXXX XXXXXXXXXXXXXX XXXXX XXXXXXXXXXXX XXXXXXXX XXXXXXX XXX XXXXXX (+XX% XX £X.X XXXXXXX), XXXXXX XXX XXXX XXXX XXXXXXXXXXXXX, XXXXX XXX XXXXXXXX XXXX XXXXXXX XXXXXXXXXXXXXXX XX XXXX, (£XXX XXXXXXX +XX% XX X XXX XXXXX XXXXX) XXX XXXXXXXX (+XX% XX £X.X XXXXXXX).

XXXXXXXX XX £X:
X) +XXX XXXXXXX (XXXXXXX XX XXX XX XXXXXXXXXXXXXX & XXXXXXXXXX, & XX XXXXXXXX XX XXXXX)
X) +XXX XXXXXXXXXXX (XXXXXXX XX XXX XX XXXXXXXXXXXXXX & XXXXXXXXXX, & XX XXXXXXXX XX XXXXX)

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXXXX XX XXXXXXXX, XXX XXX XXXXXXXXX XX XXXXXXXX XXX XXXXXXX XXXXXXXX, XXXX XX% XX £X.X XXXXXXX, XXXXXX XX XXXXX XX XXX XXX XXXXX XXXX XX XX% XX £XXX XXXXXXX, XXXX?XXXX XXXX XXX XXX XXXXXXXXXX. XXXXXXXX XX XXXX XXX XXXX XXXXXXXX XXXX XXXX-XXXX XXXXXXXX XXXX XXXX XXXXXXXXXXXX
XXXX XX XXX XXXXX XXX XXXXX XX XXXXXXXXXX XXXXXXXX XX XXXXXXX XXXXXXXX. XXX XXXXXXX XX XXXXXXX XX XXX XX XXX’X XXXXXXXXXX XXXXXX XXX XXXXXXXX XX XX XXX XXXXXX XX XXXX.

XXXXXX: XX XXXX XXXXXXX (X XXX XXXX):
XXXXX XX XXXXXXXX, XXX XXX XXXXXXXXX XX XXXXXXXX XXX XXXXXXX XXXXXXXX, XXXX XX% XX £X.X XXXXXXX, XXXXXX XX XXXXX XX XXX XXX XXXXX XXXX XX XX% XX £XXX XXXXXXX. XXX XXXXXXX XXXXXXX XX XXXXXXX XX XXX XXX’X XXXXXXXXXX XXXXXX XXX XXXXXXXX XX XXXXXX XXX-XXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX XXXXXXXXXXXX (X XXX XXXX), XXXXX XX:
* XXX XXXX (‘XXXXX XXX’) XXXXXXXX XXXXXXXXXX XXXXXXXX XX XXX. ‘XX
* XXXXXXXX XX (XXXXXXXX) XXXXX XXX ’XX

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXX XXXXXXXX XX XXX’X XXX XXXXXXXXX XX XXX XXXXXXXX XX XXXXXXX XXXXXXXXXXX XX XXX XXX, XX XXXXXXX XXXXXXXXXXX XX XXXXXXXX, XXXXXXX XXX XXX XXXXXXXXX XXXXXXXXXXXX XX XXXXXXXXXX XXXXXXX XXXXXX XXX XXXXXX XX XXXX. XXXXX XXX, XXXXXXX, XXXX XXXXXXXX XXXX XX XXXXXXXX XXX XXXXXXXX XXX XXXXXXXX XX XXX XXX XX XXXXX XXXX.

XXXXXX: XX XXXX XXXXXXX (X XXX XXXX):
XXXXXXXX XXXXX XXXX XX% XX £XXX XXXXXXX, XXXXXXXXX XXX XXXXXXXXXXXX XX XXXXXXX XXXXXXXXXXX XX XXX XXXXXXX XX XXX XXX XX XXXX.

Company Specific NameCardiovascular and urogenital

XXXXXXXX XX £X:
X) +XXXX XXXXXXXXXXXXXX XXX XXXXXXXXXX.

XXXX
X) -XX XXXXXXX (XXXXXXXXXX XX XXXXXXXX XXXXX 'XXXXXXXX XXXXXXX')
X) -XXX XXXXXX/XXXXXXX (XXXXXXXXXX XX XXXXXXXX XXXXX XXXXXX-XXXXXXX)
X) -XX XXXXXXXX (XXXXXXXXXX XX XXXXXXXX XXXXX 'XXXXXXXX XXXXXXX')
X) -XXX XXXXXXX (XXXXXXXXXX XX XXXXXXXX XXXXX XXXXX)
X) -XXX XXXXXXXXXXX (XXXXXXXXXX XX XXXXXXXX XXXXX XXXXX)

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000.  This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NamePharmaceuticals

Company Specific NameCentral Nervous System

XXXXXXXX XX £X:
X) +XXXXX XXXXXXXXX XXXXXXXXXXXXXXX.

XXXXX XXXXXXX XXXXX XXXXXXXXXX XX XX-XXXXXXXXX XXX XXXXXXXXX.
X) +XX XXXXXXX XX-XXXXXXXXX XXXXXX
X) +XXX XXXXXXX/ XXXXXX XX-XXXXXXXXX XXXXXX.
X) +XX XXXXXXXX XX-XXXXXXXXX XXXXXX.
X) +XX XXXXXXXXX XXXXXX & XXXXXXXX XXXXXXXXX.

XXXXXXXX XX £X:
X) +XXXX XXX XXXXX XXXXXXXXX XX XXX
X) +XXX XXX XXXXXXX XXXXXXX
X) +XXX XXXXXXX XXXXXXXXX

XXXXXXXX XX £X:
X) +XXXXX XXXXXXXXX XXXXXXXXXXXXXXX.

XXXXX XXXXXXX XXXXX XXXXXXXXXX XX XX-XXXXXXXXX XXX XXXXXXXXX.
X) +XX XXXXXXX XX-XXXXXXXXX XXXXXX
X) +XXX XXXXXXX/ XXXXXX XX-XXXXXXXXX XXXXXX.
X) +XX XXXXXXXX XX-XXXXXXXXX XXXXXX.
X) XXXXXXXXX XXXXXX & XXXXXXXX XXXXXXXXX.

XXXXXXXX XX £X:
X) +XXX XXX XXXXXXXXXXXXXX - XXXXXXXX XXXXXXXXX XXXX XXXX XXXXXXXXX XXXXX (+XX) XXXX XXXXX XXXXXXXXXXX XXX XXXXXXXXXXXXXX XXXXXXX, XXXXX XXXX XXXX XXXXXXXXXX XXXXX XX XXXX XXXXXXXXX XXX XXXXXXXXXXXXXX XXXXXXXX (+XXX) XXXXX XXXX XXXXXXXXX XXXXX XXX XXXXXXXXXXXXXX XXXXXXXX (+XX).

Company Specific NameMetabolic (plus Zofran; minus Avandia)

XXXXXXXX XX £X:
X) +XXXX XXXXXXXXX
XXXX
X) +XXX XXXXXX XXXXX (XXXXXXX XX XXX XX XXXXXXXX XXX XXXXXX, & XX XXXXXXXX XX XXXXXX-XXXXXXXXXX)
X) +XXX XXX XXXXXX-XXXXXXXXXX - XXXXXXXX XXXXXXXXX XXXX XXXXX (+XX) XXXX XXXXX XXXXXXXXXXX XXX XXXXXXXXXXXXXXXX XXXXXXXX, XXXXX XXXX XXXX XXXXXXXXXX XXXXX XX XXXX XXXXXXXXX XXX XXXXXXXXXXXXXXXX XXXXXXXX (+XXX) XXXXX XXXX XXXXXXXXX XXXXX XXXXXXXXX XXX XXXX (+XX).
X)  +XX XXX XXXXXX XXXXXXXXXX (XXXX)
XXXXX
X) -XXX XXXXXXX (XXXXXXX XX XXX XX XXXXXXXXX, & XX XXXXXXXX XX XXXXXXXXX)
X) -XXX XXXXXXXXX (XXXXXXX XX XXX XX XXXXXXXXX, & XX XXXXXXXX XX XXXXXXXXX)
X) -XXX XXXXXXX/XXXXXX (XXXXXXXXXX XX XXXXXXXX XXXXX 'XXXXXXXX XXXXXXX')

Company Specific NameArthritis

Company Specific NameOncology & Emesis (less Zofran)

XXXXXXXX £X:
X) +XXX XXXXXXXX & XXXXXX
XXXXX
X) -XXX XXXXXX XXXXX (XXXXXXX XX XXX XX XXXXXXXX XXX XXXXXX, & XX XXXXXXXX XX XXXXXX-XXXXXXXXXX)

Company Specific NameRespiratory

XXXXXXXX XX £X:
X) +XXXX XXXXXXXXXXX
XXXX
X) +XXX XXX XXXXXXXXXXX XXXXX - XXXXXXXX XXXXXXXXX XXXXXXX XXXXX XXXXX (+XX) XXXX XXXXX XXXXXXXXXXX XXX XXXXXXXXXXX XXXXX XXXXX, XXXXX XXXX XXXX XXXXXXXXXX XXXXX XX XXXX XXXXXXXXX XXX XXXXXXXXXXX XXXXX (+XXX) XXXXX XXXX XXXXXXXXX XXXXX XXXXXXXXX XXX XXXXXXX XXXXX XXXXX (+XX).

Company Specific NameAnti-infectives & Vaccines

XXXXXXXX XX £X:
X) +XXXX XXXX-XXXXXXXXXX.
X) +XXXX XXXX-XXXXXX
X) +XXXX XXXXXXXX.